Key takeaway: The earnings call for Blue Jet Healthcare Limited on May 25, 2026, highlighted FY26 as a foundational year for growth, with management focusing on investments in manufacturing, R&D, and customer engagement. Management reported a mixed operating environment, with the PI/API business affected by inventory normalization, while the contrast media segment showed strong growth. The Vizag greenfield expansion project commenced, aimed at enhancing capacity for APIs and intermediates. Financially, Q4 revenues were INR 235 crores, a 22% quarter-over-quarter increase but a 31% year-over-year decline. Full-year revenues were INR 947 crores, down 8% from FY25. The contrast media segment saw a 91% year-over-year revenue increase, while the PI/API segment declined by 35%. Management expressed optimism for FY27, citing improved visibility and ongoing investments in growth initiatives.

Key takeaway: On May 25, 2026, Blue Jet Healthcare Limited submitted an investor presentation detailing its financial results for the quarter and fiscal year ending March 31, 2026. The presentation highlighted a quarter-on-quarter revenue increase of 22% to Rs. 2,347 million, with EBITDA rising by 52% to Rs. 713 million and PAT increasing by 60% to Rs. 643 million. However, year-on-year comparisons showed a 31% decline in revenue and a 49% decrease in EBITDA, attributed to reduced sales in the Pharma Intermediates segment. For FY26, total revenue was reported at Rs. 9,473 million, down 8% from FY25, with EBITDA and PAT also declining. The company noted strong visibility on underlying demand and ongoing projects, including a new R&D center and a Vizag project. The presentation emphasized the company's focus on growth in its Contrast Media and High-Intensity Sweeteners segments.

Key takeaway: On February 13, 2026, Blue Jet Healthcare Limited held its Q3 FY26 earnings conference call, where management provided updates on various projects and financial performance. The groundbreaking ceremony for the Vizag Greenfield project is scheduled for this month, with a total investment plan of Rs. 1,000 crores over the next three to four years. The Hyderabad R&D expansion is set to begin in Q3 FY27. Financially, revenue from operations decreased by 40% year-on-year, while EBITDA and PAT also saw declines of 62% and 39%, respectively. However, there was a 16% increase in revenue quarter-on-quarter. Management highlighted the stability of their flagship product and the ongoing development of new artificial sweeteners. The call concluded with management expressing optimism about future growth despite current challenges, including customer de-stocking and supply chain realignment.